contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

           

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

ardenHEADER2.jpg

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

"No good. Diabetes." - Donald Trump 

Scott Benner

Have diabetes? Trump thinks that makes you unable to perform your job.

This blog post will be quoting a reporter from Jonathan Swan at Axios.com. Jonathan is citing sources who say that Donald Trump believes he'll be replacing four supreme court justices during his term. 

"Asked how he comes to that jaw-dropping number, Trump mentions the obvious: he's already replaced Antonin Scalia with Neil Gorsuch, and there are rumors Anthony Kennedy will retire."

"Ok," one source told Trump, "so that's two. Who are the others?"

"Ginsburg," Trump replied. "What does she weigh? 60 pounds?"

"Who's the fourth?" the source asked.

"Sotomayor," Trump said, referring to the relatively recently-appointed Obama justice, whose name is rarely, if ever, mentioned in speculation about the next justice to be replaced. 

Trump explained...

"Her health, No good. Diabetes."

In ten years of writing about type 1 diabetes I've perhaps posted twice about something even remotely political. But today it is being reported that the President of the United States believes that type 1 diabetes is an impediment to acting as a Supreme Court Justice. I would like to know what further bias Trump holds against people living with chronic illness. If Justice Sotomayor can lose her job for having type 1, can you? Maybe she doesn't deserve healthcare? Why is it so easy for Trump to dismiss a human being because they happen to have type 1 diabetes? Why is the person making decisions about how the country receives healthcare so painfully unaware of what it means to live with type 1 diabetes. 

Please consider sharing this image on your social media channels and ask news agencies to look deeper into the Axios story. Use the hashtag #RespectUs

respectus.jpg

Johnson & Johnson (Animas) Exits Insulin Pump Business

Scott Benner

Ping, Poof, Pow!!!

From Reuters - Johnson & Johnson’s diabetes care unit, which makes insulin pumps, said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer.

The entire story is here on Reuters.

More from MarketWatch

1.1.2.1_Ping.jpg

Johnson & Johnson's Animas Corp. said Thursday it plans to close operations and exit the insulin pump business. The company will discontinue the manufacturing and sale of its Animas, Vibe and OneTouch Ping insulin pumps. Animas said Medtronic PLC MDT, +1.30% will help facilitate a transition for the 90,000 patients who use Animas pumps, and who will be offered the option to transfer to a Medtronic pump. Animas employs 410 people around the world. The move comes as part of J&J's strategic review announced in January, in which it is continuing to evaluate options for LifeScan, a blood glucose monitoring company with the OneTouch brand of products. J&J's stock was inactive in premarket trade. It has slipped 0.6% over the past three months, while the SPDR Health Care Select Sector ETF XLV, -0.10% has gained 3.9% and the S&P 500 SPX, +0.50% has advanced 4.3%.


Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin

Scott Benner

Press release 

Plainsboro, N.J. (September 29, 2017) – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp® (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.

IMG_0598.JPG

Fiasp® Can be dosed at the beginning of a meal or within 20 minutes after starting a meal. Fiasp® is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes.

Fiasp® will be available in a pre-filled delivery device FlexTouch pen and a 10 mL vial.

Many adults with type 1 and type 2 diabetes struggle with blood sugar control after meals. The result of this has led to many people with diabetes not achieving their target A1C.

 “With Fiasp®, we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” said Bruce Bode, MD FACE, President of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine. “The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management.”

Fiasp® will launch at the same list price as NovoLog® and will be offered with a Savings Card program for eligible patients with commercial insurance to reduce co-pays. Fiasp® will also be available to eligible patients through the Novo Nordisk Patient Assistance Program. Patients and caregivers can obtain more information and access to the Novo Nordisk Patient Assistance Program by calling toll free at 866-310-7549.

The entire release is here.

 

Dexcom Opens their API to Third-party Developers

Scott Benner

Dexcom leads the way in diabetes yet again...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (CGM), announced today the availability of a public API, empowering third-party developers to connect patient-authorized CGM data into a broad range of software applications. This pioneering approach to CGM data sharing is intended to enable a rich ecosystem of novel solutions and put the user in control of where and how they interact with their glucose data.

"In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes," said Annika Jimenez, Senior Vice President of Data, Dexcom. "Dexcom believes in data mobility and customer choice. It also believes that the API opens up opportunities to drive Dexcom CGM data into the heart of new digital solutions for payers, providers, and most importantly people with diabetes."

Get to it diabetes app developers, go make something great!

Dexcom Dev Page


New Apple Ad features Dexcom: Here is why that is important to you

Scott Benner

"my daughter was recently diagnosed with type 1 diabetes"

People living with T1D are understandably excited to hear the words, "my daughter was recently diagnosed with type 1 diabetes" in an Apple ad... but that is just the beginning of why this Apple Watch advertisement should get your heart pumping.

The percentage of people with type 1 using continuous glucose monitoring technology is still relatively low. The barriers to adoption are multivariable. Cost, lack of insurance coverage, misunderstanding of what the technology brings to your life and plain just not knowing that it exists are but a few. The truth however is that even if you never find your way to a CGM this quick video, in my opinion, should still make you happy. Here's why.

We finally have a device manufacturer in the diabetes world who moved beyond the diabetes world. When Dexcom searched for others whose collaboration might improve their product, they didn't just form a relationship with a little start-up. They formed a relationship with Apple. The mention of Apple Watch integration with Dexcom in this ad, in my opinion, is not random. The mention didn't happen just because someone wrote a letter. It is there on purpose. This is Apple telling us what is important to them and a signal of where they are focusing their efforts when it comes to the health space. 

The company that put a smartphone into most every hand on the plant and the company that is hugely responsible for the technology that keeps my daughter healthy, they are dating. I think we are all going to like what their future children grow up to be. I'm even more excited when I think about the relationship that Dexcom has with Omnipod and the ways that the Apple connection could improve all aspects of the tech that helps to keep Arden's BGs where we want them. 

For the moment its great to hear diabetes in the mainstream in such a positive way, but I think that this is only the beginning of how Dexcom and Apple are going to make us smile. It is important to note that Dexcom advertises on the Juicebox Podcast but that I wrote this piece on my own.